ABCG2 and colorectal carcinoma: From a clinical applicability perspective, precise discrimination of CRC patients into ABCC4/ABCG2 High subgroups may be another factor enabling the selection of correct and appropriate personalised therapy, including a mix of chemo and immunotherapy and identifying the most likely metastatic site.